We still face many difficulties in the treatment of advanced hepatocellular carcinoma (HCC). Especially for portal vein tumor thrombus, vena cava tumor thrombus and tumors invaded by biliary tract, there is no unified treatment opinion. Numerous approaches are used to treat advanced HCC with vascular invasion, but efficacy varies widely due to patient heterogeneity. Moreover, for patients with different tumors, even with the same treatment, the efficacy varies greatly. With the development of targeted immunotherapy, more and more patients have received targeted immunotherapy, but the efficacy is still unsatisfactory. Various local treatments have been reported in the literature to play an important role in advanced HCC. When local therapy is combined with systemic therapy or local therapy combined with local therapy, the efficacy of advanced HCC is further improved. For mid-stage HCC, the guidelines do not recommend the use of ablation therapy, but with the development of targeted immunotherapy, we found that some patients can achieve good results by ablation combined with antiangiogenic therapy and immunotherapy. However, relevant clinical experience is still rarely reported.
Firstly, we hope to further explore local combined systemic therapy for advanced HCC to improve the survival rate. In this Research Topic, you are welcome to report how to reasonably carry out local and systemic treatment, such as the order of local and systemic treatment; how to improve the effect of immunotherapy through local treatment; how to replace local treatment or regain control of the disease after disease progression who underwent systemic treatment. Secondly, we hope to explore the role of ablation therapy in mid-stage HCC and how to closely combine ablation therapy with systemic therapy to treat patients with mid-stage HCC more effectively.
We welcome submissions covering, but not limited to, the following sub-topics:
1. Efficacy analysis of internal beam radiotherapy (including 90Y and 125I seed) combined with systemic therapy for HCC with portal vein tumor thrombus
2. Efficacy analysis of external beam radiotherapy combined with systemic therapy for HCC with portal vein tumor thrombus
3. Efficacy analysis of transarterial chemoembolization (TACE, including c-TACE and D-TACE) combined with systemic therapy for HCC with portal vein tumor thrombus
4. Combination of ablation therapy and systemic therapy for mid-stage HCC
5. Analysis of transformation therapy of local combined systemic therapy for advanced HCC
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
We still face many difficulties in the treatment of advanced hepatocellular carcinoma (HCC). Especially for portal vein tumor thrombus, vena cava tumor thrombus and tumors invaded by biliary tract, there is no unified treatment opinion. Numerous approaches are used to treat advanced HCC with vascular invasion, but efficacy varies widely due to patient heterogeneity. Moreover, for patients with different tumors, even with the same treatment, the efficacy varies greatly. With the development of targeted immunotherapy, more and more patients have received targeted immunotherapy, but the efficacy is still unsatisfactory. Various local treatments have been reported in the literature to play an important role in advanced HCC. When local therapy is combined with systemic therapy or local therapy combined with local therapy, the efficacy of advanced HCC is further improved. For mid-stage HCC, the guidelines do not recommend the use of ablation therapy, but with the development of targeted immunotherapy, we found that some patients can achieve good results by ablation combined with antiangiogenic therapy and immunotherapy. However, relevant clinical experience is still rarely reported.
Firstly, we hope to further explore local combined systemic therapy for advanced HCC to improve the survival rate. In this Research Topic, you are welcome to report how to reasonably carry out local and systemic treatment, such as the order of local and systemic treatment; how to improve the effect of immunotherapy through local treatment; how to replace local treatment or regain control of the disease after disease progression who underwent systemic treatment. Secondly, we hope to explore the role of ablation therapy in mid-stage HCC and how to closely combine ablation therapy with systemic therapy to treat patients with mid-stage HCC more effectively.
We welcome submissions covering, but not limited to, the following sub-topics:
1. Efficacy analysis of internal beam radiotherapy (including 90Y and 125I seed) combined with systemic therapy for HCC with portal vein tumor thrombus
2. Efficacy analysis of external beam radiotherapy combined with systemic therapy for HCC with portal vein tumor thrombus
3. Efficacy analysis of transarterial chemoembolization (TACE, including c-TACE and D-TACE) combined with systemic therapy for HCC with portal vein tumor thrombus
4. Combination of ablation therapy and systemic therapy for mid-stage HCC
5. Analysis of transformation therapy of local combined systemic therapy for advanced HCC
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
